Clinical Trial Detail

NCT ID NCT02436668
Title Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pharmacyclics
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel

Ibrutinib

Age Groups: adult

No variant requirements are available.